ISOP 2011

This week I have been at the International Society of Pharmacovigilance's 2011 meeting in Istanbul. My colleagues and I have been presenting data on missed doses (adults and children), causality and prevention of adverse drug reactions, the use of rivaroxoban for total knee replacement, and patient internet accounts of serious…

Xigris Grounded

Drotrecogin alfa (Xigris) has been withdrawn from the market, because it doesn't work. It was granted a licence in the full knowledge that insufficient data existed for a standard licence, and was under yearly review by the European Medicines Agency. It was restricted for use in those with severe sepsis…

EU Pharmacovigilance

The BBC's Democracy Live have put up the EU debate on pharmacovigilance. Interestingly, one of the outcomes is some legal backing to a black symbol, with the statement "This medicinal product is subject to additional monitoring." In the UK, that is the black triangle. I hope it doesn't change. EU…

Paracetamol: Recall bias and media bias

Just a short note. A couple of years ago there was a great deal of fuss about paracetamol and a possible link with asthma in children [Lancet]. The study reported on was a large retrospective study (205 487 children) involving surveying parents about their children's previous paracetamol use and symptoms…